KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
4/6/2011 10:10:30 AM
More...
|
OncoVista Innovative Therapies, Inc. Sells AdnaGen Subsidiary: Total Sale Price Could Reach $65 Million Over Three Years When Milestones Achieved
11/11/2010 8:13:28 AM
More...
|
OncoVista Innovative Therapies, Inc. Subsidiary AdnaGen Inks Exclusive Agreement with TATAA Molecular Diagnostics
1/26/2010 9:31:13 AM
More...
|
LAB21 Limited to Provide AdnaGen's CE-Marked System for the Detection and Analysis of Circulating Tumor Cells (CTCs) in the United Kingdom and Ireland
8/10/2009 1:52:29 PM
More...
|
OncoVista Innovative Therapies, Inc. Announces the Initiation of Clinical Development of AdnaGen's Breast Cancer Circulating Tumor Cells (CTCs) Diagnostic Technology in Women with High-Risk Locally Advanced Breast Cancer
7/24/2009 8:49:52 AM
More...
|
AdnaGen and OncoVista Innovative Therapies, Inc., Announce the Issuance in the U.S. of a Key Patent Related to Technology for the Detection and Analysis of Circulating Tumor Cells
3/27/2009 8:43:10 AM
More...
|
Sysmex Europe GmbH to Distribute Products for the Analysis of Circulating Tumor Cells in Different Tumor Entities Developed by AdnaGen, a Subsidiary of OncoVista Innovative Therapies, Inc.
1/29/2009 10:49:23 AM
More...
|
OncoVista Innovative Therapies, Inc. Announces Submission of Request for Pre-IDE Determination Meeting with FDA for AdnaGen's AdnaTest Breast Cancer Device for Detection of Circulating Breast Tumor Cells
5/6/2008 8:29:16 AM
More...
|
OncoVista Innovative Therapies, Inc. Announces Appointment of AdnaGen Chief Executive Officer
4/11/2008 8:33:27 AM
More...
|
OncoVista Increases Its Share in AdnaGen
12/17/2007 11:44:54 AM
More...
|
|